| Literature DB >> 27220335 |
David S Goldstein1, Yunden Jinsmaa2, Patti Sullivan2, Courtney Holmes2, Irwin J Kopin2, Yehonatan Sharabi2,3.
Abstract
The catecholaldehyde hypothesis predicts that monoamine oxidase (MAO) inhibition should slow the progression of Parkinson's disease, by decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). Inhibiting MAO, however, diverts the fate of cytoplasmic dopamine toward potentially harmful spontaneous oxidation products, indicated by increased 5-S-cysteinyl-dopamine (Cys-DA) levels. 3,4-Dihydroxyphenylethanol (hydroxytyrosol) is an abundant anti-oxidant phenol in constituents of the Mediterranean diet. Whether hydroxytyrosol alters enzymatic or spontaneous oxidation of dopamine has been unknown. Rat pheochromocytoma PC12 cells were incubated with hydroxytyrosol (10 µM, 180 min) alone or with the MAO-A inhibitor clorgyline (1 nM) or the MAO-B inhibitors rasagiline or selegiline (0.5 µM). Hydroxytyrosol decreased levels of DOPAL by 30 % and Cys-DA by 49 % (p < 0.0001 each). Co-incubation with hydroxytyrosol prevented the increases in Cys-DA seen with all 3 MAO inhibitors. Hydroxytyrosol therefore inhibits both enzymatic and spontaneous oxidation of endogenous dopamine and mitigates the increase in spontaneous oxidation during MAO inhibition.Entities:
Keywords: Cysteinyl-dopamine; DOPAL; DOPET; Hydroxytyrosol; Monoamine oxidase; Parkinson’s disease
Mesh:
Substances:
Year: 2016 PMID: 27220335 PMCID: PMC5125943 DOI: 10.1007/s11064-016-1959-0
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996